这是瑞辉的声明：

In a statement issued on Thursday after the Oxford data was released, Pfizer said that its own "comprehensive assessment of ongoing aggregate safety data... provided no evidence to conclude that arterial or venous thromboembolic events, with or without thrombocytopenia, are a risk associated with the use of our COVID-19 vaccine."

Pfizer noted that a CDC review of data had detected slightly more cases of CVT in people given the Johnson & Johnson vaccine in the U.S., but "no similar findings have been observed with the authorized Pfizer-BioNTech vaccine."